XML 43 R34.htm IDEA: XBRL DOCUMENT
v3.23.3

Acquisition - Additional Information (Details) - Bioniz - USD ($) |  |  | 3 Months Ended | 9 Months Ended |
--- | --- | --- | --- | --- | ---
Aug. 14, 2023 | Feb. 14, 2022 | Sep. 30, 2023 | Sep. 30, 2022 | Sep. 30, 2023 | Sep. 30, 2022 | Dec. 31, 2022
Business Acquisition [Line Items] |  |  |  |  |  |  |
Business acquisition, common stock shares issued |  | 4,820,230 |  |  |  |  |
Business acquisition, term for finalization after the closing |  | 18 months |  |  |  |  |
Transaction costs |  |  |  | $ 0 |  | $ 400,000 |
Shares of common stock issued | 849,133 |  |  |  |  |  |
Adjustment to in-process research and development |  |  | $ 0 |  | $ 0 |  |
Adjustment to additional paid-in capital |  |  | $ 0 |  | $ 0 |  | $ 0
18 Months after Closing |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |
Business acquisition, common stock shares issued |  | 879,252 |  |  |  |  |
Achievement of Regulatory Events |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |
Contingent payments |  | $ 57,500,000 |  |  |  |  |
Achievement of Commercialization Events |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |
Contingent payments |  | $ 250,000,000 |  |  |  |  |
Maximum |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |
Business acquisition, common stock shares issued |  | 5,699,492 |  |  |  |  |

X
- Definition Adjustment to additional paid-in capital. + References No definition available. + Details
Name: | eq_AdjustmentToAdditionalPaidInCapital
Namespace Prefix: | eq_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Adjustment to in-process research and development. + References No definition available. + Details
Name: | eq_AdjustmentToInProcessResearchAndDevelopment
Namespace Prefix: | eq_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Terms of merger agreement. + References No definition available. + Details
Name: | eq_TermsOfMergerAgreement
Namespace Prefix: | eq_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of shares of equity interests issued or issuable to acquire entity. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(4) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1 + Details
Name: | us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479907/805-20-50-5 + Details
Name: | us-gaap_BusinessAcquisitionLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 25 -Paragraph 23 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479405/805-10-25-23 + Details
Name: | us-gaap_BusinessCombinationAcquisitionRelatedCosts
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (c)(3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1 + Details
Name: | us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Number of shares of stock issued during the period pursuant to acquisitions. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details
Name: | us-gaap_StockIssuedDuringPeriodSharesAcquisitions
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=eq_BionizTherapeuticsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=eq_EighteenMonthsAfterClosingMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=eq_ContingentConsiderationForAchievementOfRegulatoryEventsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=eq_ContingentConsiderationForAchievementOfCommercializationEventsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |